CRISPR Technology Market Report 2025

The CRISPR technology market size has grown exponentially in recent years. It will grow from $2.05 billion in 2024 to $2.53 billion in 2025 at a compound annual growth rate (CAGR) of 23.7%. The growth in the historic period can be attributed to a rise in funding and an increase in pharmaceutical R&D expenditure.

The CRISPR technology market size is expected to see exponential growth in the next few years. It will grow to $5.75 billion in 2029 at a compound annual growth rate (CAGR) of 22.7%. The growth in the forecast period can be attributed to rising demand for gene therapeutics, technological advancements in the fields of genome editing, growing demand for the discovery of drugs, increasing demand for CRISPR in diagnostics, rising demand for CRISPR technologies in agriculture applications, and rising adoption of CRISPR technologies. Major trends in the forecast period include developing innovative next-generation technology, developing improved CRISPR technologies for better results in new drug developments, using AI to improve the efficiency and accuracy of gene editing with CRISPR, investing in new approaches such as IDMseq to increase accuracy, and establishing collaborations with companies.

The adoption of CRISPR technology as a diagnostic tool is poised to elevate the market's trajectory. Notably, the Sherlock CRISPR SARS-CoV-2 kit stands out as the inaugural diagnostic kit employing CRISPR technology for infectious diseases, particularly COVID-19. In February 2021, the FDA granted emergency use authorization to Sherlock BioSciences Inc.'s CRISPR-based SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) diagnostic test. This kit exhibits high specificity and sensitivity, targeting RNA or DNA sequences of the SARS-CoV-2 virus with precision from various specimens. Its reliability in avoiding false negatives or positives positions CRISPR technology as a pivotal player in infectious disease diagnosis, fostering a surge in demand for CRISPR products and services.

Leading companies in the CRISPR technology market are pursuing a strategic partnership approach to develop treatments for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). Strategic partnerships involve companies utilizing each other’s strengths and resources to achieve mutual advantages and success. For example, in November 2023, Vertex, a UK-based call center company, formed a partnership with CRISPR Therapeutics, a biotechnology firm based in Switzerland. This collaboration aims to create innovative solutions and has led to the launch of the CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™. This therapy, known as CASGEVY (exagamglogene autotemcel), employs CRISPR/Cas9 technology to modify genes in hematopoietic stem cells, facilitating the production of functional hemoglobin. This advancement has the potential to significantly reduce or eliminate the painful vaso-occlusive crises linked to sickle cell disease and lessen the necessity for blood transfusions in patients with transfusion-dependent beta-thalassemia.

Major companies in the CRISPR technology market are concentrating on creating advanced gene editing tools to improve precision in genomic modifications for use in medicine, agriculture, and biotechnology. Gene-editing tools are technologies that enable precise alterations to an organism's DNA, facilitating the addition, deletion, or modification of genetic material. Tools like CRISPR-Cas9 allow for targeted changes to genes, pushing forward research in genetics, medicine, and biotechnology. For example, in May 2024, Profluent Bio Inc., an Ireland-based AI-driven protein design firm, introduced OpenCRISPR-1 to Edit the Human Genome. This tool provides significant advantages in gene editing by achieving a 95% reduction in off-target effects, enhancing the accuracy of genetic modifications compared to conventional CRISPR systems. Its open-source nature also enables researchers globally to tailor and refine the tool for various uses, encouraging ethical applications and speeding up the creation of new therapies for genetic disorders.

In February 2023, Sherlock Biosciences, a US-based health company dedicated to developing diagnostic tools that make health information more accessible, accurate, and affordable, acquired Sense Biodetection for an undisclosed sum. This acquisition is aimed at speeding up the development of user-friendly, CRISPR-based diagnostic tools that provide consumers with accurate health testing. Sense Biodetection Limited is a UK-based molecular diagnostics firm specializing in rapid, point-of-care diagnostic solutions.

Major companies operating in the CRISPR technology market include Crispr Therapeutics, Thermo Fisher Scientific, Intellia Therapeutics, Horizon Discovery, Synthego Corporation, Integrated Dna Technology (Danaher), Editas Medicine, GenScript, Agilent Technologies, New England Biolabs, CSIR-Institute of Genomics & Integrative Biology (IGIB), Strand Life Sciences Pvt. Ltd., Bio Palette Co. Ltd., CSL Limited, C4U Co. Ltd., BGI Group, Churchi Genome Engineering and Therapeutic Research Center., Beam Therapeutics Inc., Eurofins Genomics India, Setsurotech Co. Ltd., Merck Japan, Institut Pasteur, CureVac, Cellectis, BiovelocITA S.r.l., Evotec A.G., SNIPR Biome, Oxford Genetics, ERS Genomics, Alia Therapeutics, Solvo, BioTalentum, Rosneft, BIOCAD, BioVendor, Research & Diagnostic Products, Contipro, Lonza Biotec, Sotio, Selvita, BioVentures Institute Ltd, Sigma-Aldrich, Poseida Therapeutics, NanoCellect Biomedical, Sherlock Biosciences, Repare Therapeutics, Inscripta Inc., Santa Cruz Biotechnology, Caribou Biosciences Inc., Egenesis Inc., Homology Medicines, System Biosciences, Takara Bio USA Inc., Inari Agriculture Inc., Precision BioSciences, Cell Microsystems Inc., GeneCopoeia Inc., Horizon Discovery Group, Merck KGaA, Origene Technologies Inc., Pluristem Therapeutics Inc.

North America was the largest region in the CRISPR technology market in 2024. Western Europe was the second largest region in the global CRISPR technology market. The regions covered in the CRISPR technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the CRISPR technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The CRISPR technology market includes revenue earned by CRISPR Screening Libraries, CRISPR Positive Controls, CRISPR Negative Controls, and Gene-specific Knockout Kits. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

CRISPR technology is a groundbreaking gene-editing tool that allows for precise modifications of DNA in living organisms. It is utilized to alter genes for a range of applications, including disease treatment, enhancements in agriculture, and biological research.

The primary product categories in CRISPR technology include design tools, plasmids and vectors, CAS9 and G-RNA components, and delivery systems. CRISPR-Cas9 is an innovative tool allowing scientists to edit specific genome sections by adding, removing, or altering DNA sequences. Applications encompass genome editing, genetic engineering, agricultural biotechnology, among others, and find utility across various sectors including industrial biotech, biological and agricultural research, therapeutics, and drug discovery.

The CRISPR technology market research report is one of a series of new reports that provides CRISPR technology market statistics, including CRISPR technology industry global market size, regional shares, competitors with a CRISPR technology market share, detailed CRISPR technology market segments, market trends and opportunities, and any further data you may need to thrive in the CRISPR technology industry. This CRISPR technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.